CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT07278479
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:00.460021+00:00
- Published At
- 2026-04-08T00:00:00+00:00
- Record Updated At
- 2026-04-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Large Cell Neuroendocrine Carcinoma", "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)", "Small Cell Lung Cancer (SCLC)", "Gastroenteropancreatic NEC (GEP NEC)", "NEC of the Bladder", "Other DLL3 Expressing epNEC"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-08"- protocolSection.identificationModule.nctId
"NCT07278479"- protocolSection.identificationModule.officialTitle
"A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.